The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.
Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.
Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.